GIP and type 1 diabetes mellitus: This analysis identified 943.456 subjects with T1D from 2010 to 2023, showing that the percentage of T1D patients who were prescribed GLP-1 RAs (dulaglutide, albiglutide, lixisenatide, exenatide, liraglutide, and semaglutide) and the dual GIP/GLP-1 RA tirzepatide increased significantly from 0.3% in 2010 to 6.6% by 2023.